Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Joy Ho

Showing results (21-30 of 81) with videos related to

Pageof 9
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|May 3, 2024
Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment-An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and RelapseP Joy Ho, Andrew Spencer, Peter Mollee, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 15, 2025
New Zealand Multiple Myeloma Patients Demonstrate Inferior Outcomes When Compared to Australian Counterparts - A Retrospective Cohort Study from the Myeloma and Related Diseases Registry (MRDR)Jian Li, Yayehirad Melsew, Cameron Wellard, et al.
Frontiers in Oncology|February 5, 2025
Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in AustraliaP Joy Ho, Hang Quach, M Hasib Sidiqi, et al.
Haematologica|October 5, 2023
Single-cell analysis of the CD8<sup>+</sup> T-cell compartment in multiple myeloma reveals disease specific changes are chiefly restricted to a CD69<sup>-</sup> subset suggesting potent cytotoxic effectors exist within the tumor bedJames Favaloro, Christian E Bryant, Edward Abadir, et al.
Leukemia & Lymphoma|February 18, 2014
Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocolJay Hocking, Anthony P Schwarer, Robin Gasiorowski, et al.
Hemasphere|November 15, 2019
Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion-dependent anemia: the TIMES studyP Joy Ho, Devendra Hiwase, Raj Ramakrishna, et al.
British Journal of Haematology|July 5, 2024
The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real-world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR)P Joy Ho, Elizabeth Moore, Cameron Wellard, et al.
Leukemia & Lymphoma|March 15, 2014
Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myelomaJames Favaloro, Tulita Liyadipitiya, Ross Brown, et al.
European Journal of Haematology|August 19, 2016
Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study)P Joy Ho, Lay Tay, Juliana Teo, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2021
The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR)Krystal Bergin, Cameron Wellard, Elizabeth Moore, et al.
Pageof 9

Showing results (21-30 of 81) with videos related to

Sort By:
Pageof 9
Clinical Lymphoma, Myeloma & Leukemia|May 3, 2024
Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment-An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and RelapseP Joy Ho, Andrew Spencer, Peter Mollee, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 15, 2025
New Zealand Multiple Myeloma Patients Demonstrate Inferior Outcomes When Compared to Australian Counterparts - A Retrospective Cohort Study from the Myeloma and Related Diseases Registry (MRDR)Jian Li, Yayehirad Melsew, Cameron Wellard, et al.
Frontiers in Oncology|February 5, 2025
Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in AustraliaP Joy Ho, Hang Quach, M Hasib Sidiqi, et al.
Haematologica|October 5, 2023
Single-cell analysis of the CD8<sup>+</sup> T-cell compartment in multiple myeloma reveals disease specific changes are chiefly restricted to a CD69<sup>-</sup> subset suggesting potent cytotoxic effectors exist within the tumor bedJames Favaloro, Christian E Bryant, Edward Abadir, et al.
Leukemia & Lymphoma|February 18, 2014
Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocolJay Hocking, Anthony P Schwarer, Robin Gasiorowski, et al.
Hemasphere|November 15, 2019
Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion-dependent anemia: the TIMES studyP Joy Ho, Devendra Hiwase, Raj Ramakrishna, et al.
British Journal of Haematology|July 5, 2024
The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real-world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR)P Joy Ho, Elizabeth Moore, Cameron Wellard, et al.
Leukemia & Lymphoma|March 15, 2014
Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myelomaJames Favaloro, Tulita Liyadipitiya, Ross Brown, et al.
European Journal of Haematology|August 19, 2016
Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study)P Joy Ho, Lay Tay, Juliana Teo, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2021
The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR)Krystal Bergin, Cameron Wellard, Elizabeth Moore, et al.
Pageof 9